Compare Summit Therapeutics Inc (SMMT) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs TotalEnergies SE — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while TotalEnergies SE trades at $86.9 (market cap $196.06B). The key difference: TotalEnergies SE is far larger — about 16.3× Summit Therapeutics Inc's market cap, and TotalEnergies SE pays a 4.82% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TTE | |
|---|---|---|
Market Cap | $12.06B | $196.06B |
Sector | Health | Energy |
52-Week High | $26.98 | $93.60 |
52-Week Low | $12.55 | $57.39 |
Enterprise Value | $11.39B | $227.06B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
TotalEnergies (TTE) trades at $87.46, down 0.57% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed quarterly beats, while revenue declined to $182.34B in 2025. The company is expanding in renewables, acquiring Shell's European onshore renewables business and partnering on a Cyprus gas field development.
TTE offers value with a P/E of 11.01 and a 57.58% buy rating from analysts, targeting $94.00. Risks include declining revenue trends, legal challenges from climate litigation, and oil price volatility. The stock presents a balanced opportunity with income from dividends but faces execution risks in energy transition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
